rct
2017
High Quality
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry A, McDermott M, Kieburtz K
Published in Neurology
Abstract
Multicenter trial of high-dose coenzyme Q10 for Huntington disease.
Methodology
Double-blind placebo-controlled 2CARE trial of coenzyme Q10 2400 mg/day in early-to-moderate Huntington disease.
Key Findings
The trial was terminated for futility with no significant clinical benefit.
Conclusions
Coenzyme Q10 is not justified as a treatment to slow functional decline in Huntington disease.
Limitations
The trial stopped early at interim futility analysis.
Supplements Studied
CoQ10
Compound
These data do not justify use of CoQ as a treatment to slow functional decline in HD.
Outcomes Measured
The trial was terminated for futility with no significant clinical benefit.
Related Health Concerns
Study Details
Year:2017
Quality Score:9/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.